These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37088604)

  • 21. Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study.
    Li X; Ostropolets A; Makadia R; Shaoibi A; Rao G; Sena AG; Martinez-Hernandez E; Delmestri A; Verhamme K; Rijnbeek PR; Duarte-Salles T; Suchard M; Ryan P; Hripcsak G; Prieto-Alhambra D
    medRxiv; 2021 Apr; ():. PubMed ID: 33791732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccine safety in Australia during the COVID-19 pandemic: Lessons learned on the frontline.
    Laemmle-Ruff I; Lewis G; Clothier HJ; Dimaguila GL; Wolthuizen M; Buttery J; Crawford NW
    Front Public Health; 2022; 10():1053637. PubMed ID: 36408022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study.
    Naveed Z; Li J; Spencer M; Wilton J; Naus M; García HAV; Otterstatter M; Janjua NZ
    CMAJ; 2022 Nov; 194(45):E1529-E1536. PubMed ID: 36410749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
    Wong HL; Hu M; Zhou CK; Lloyd PC; Amend KL; Beachler DC; Secora A; McMahill-Walraven CN; Lu Y; Wu Y; Ogilvie RP; Reich C; Djibo DA; Wan Z; Seeger JD; Akhtar S; Jiao Y; Chillarige Y; Do R; Hornberger J; Obidi J; Forshee R; Shoaibi A; Anderson SA
    Lancet; 2022 Jun; 399(10342):2191-2199. PubMed ID: 35691322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of myopericarditis following COVID-19 mRNA vaccination in a large integrated health system: A comparison of completeness and timeliness of two methods.
    Sharff KA; Dancoes DM; Longueil JL; Johnson ES; Lewis PF
    Pharmacoepidemiol Drug Saf; 2022 Aug; 31(8):921-925. PubMed ID: 35404496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting.
    Yap J; Tham MY; Poh J; Toh D; Chan CL; Lim TW; Lim SL; Chia YW; Lim YT; Choo J; Ding ZP; Foo LL; Kuo S; Lau YH; Lee A; Yeo KK
    Ann Acad Med Singap; 2022 Feb; 51(2):96-100. PubMed ID: 35224605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
    Klein NP; Lewis N; Goddard K; Fireman B; Zerbo O; Hanson KE; Donahue JG; Kharbanda EO; Naleway A; Nelson JC; Xu S; Yih WK; Glanz JM; Williams JTB; Hambidge SJ; Lewin BJ; Shimabukuro TT; DeStefano F; Weintraub ES
    JAMA; 2021 Oct; 326(14):1390-1399. PubMed ID: 34477808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature.
    Lane S; Yeomans A; Shakir S
    BMJ Open; 2022 May; 12(5):e059223. PubMed ID: 35613761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long term follow up and outcomes of Covid-19 vaccine associated myocarditis in Victoria, Australia: A clinical surveillance study.
    Shenton P; Schrader S; Smith J; Alafaci A; Cox N; Taylor A; Hare J; Jones B; Crawford NW; Buttery JP; Cheng DR;
    Vaccine; 2024 Jan; 42(3):522-528. PubMed ID: 38154991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial.
    Takuva S; Takalani A; Seocharan I; Yende-Zuma N; Reddy T; Engelbrecht I; Faesen M; Khuto K; Whyte C; Bailey V; Trivella V; Peter J; Opie J; Louw V; Rowji P; Jacobson B; Groenewald P; Dorrington RE; Laubscher R; Bradshaw D; Moultrie H; Fairall L; Sanne I; Gail-Bekker L; Gray G; Goga A; Garrett N;
    PLoS Med; 2022 Jun; 19(6):e1004024. PubMed ID: 35727802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
    Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP
    JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military.
    Montgomery J; Ryan M; Engler R; Hoffman D; McClenathan B; Collins L; Loran D; Hrncir D; Herring K; Platzer M; Adams N; Sanou A; Cooper LT
    JAMA Cardiol; 2021 Oct; 6(10):1202-1206. PubMed ID: 34185045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel : A Retrospective Cohort Study.
    Hviid A; Hansen JV; Thiesson EM; Wohlfahrt J
    Ann Intern Med; 2022 Apr; 175(4):541-546. PubMed ID: 35103482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021.
    Oster ME; Shay DK; Su JR; Gee J; Creech CB; Broder KR; Edwards K; Soslow JH; Dendy JM; Schlaudecker E; Lang SM; Barnett ED; Ruberg FL; Smith MJ; Campbell MJ; Lopes RD; Sperling LS; Baumblatt JA; Thompson DL; Marquez PL; Strid P; Woo J; Pugsley R; Reagan-Steiner S; DeStefano F; Shimabukuro TT
    JAMA; 2022 Jan; 327(4):331-340. PubMed ID: 35076665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study.
    Ab Rahman N; Lim MT; Lee FY; Lee SC; Ramli A; Saharudin SN; King TL; Anak Jam EB; Ayub NA; Sevalingam RK; Bahari R; Ibrahim NN; Mahmud F; Sivasampu S; Peariasamy KM;
    Vaccine; 2022 Jul; 40(32):4394-4402. PubMed ID: 35667917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of the Fiocruz ChAdOx COVID-19 vaccine used in a mass vaccination campaign in Botucatu, Brazil.
    Clemens SAC; Fortaleza CMCB; Crowe M; Pollard A; Tasca KI; Grotto RMT; Martins MR; Spadaro AG; Barretti P; Verstraeten T; Clemens R
    Vaccine; 2022 Nov; 40(47):6722-6729. PubMed ID: 36055876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
    Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK
    JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system.
    Chen C; Fu F; Ding L; Fang J; Xiao J
    Front Immunol; 2022; 13():938322. PubMed ID: 36172346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute Myocarditis and Pericarditis After mRNA COVID-19 Vaccinations-A Single-Centre Retrospective Analysis.
    Wassif M; Lo P; Satouris P; Swan L; Tardo D; Kovacic JC; Muller D; Muthiah K; Kotlyar E; Bart NK
    Heart Lung Circ; 2023 Apr; 32(4):467-479. PubMed ID: 36841638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.